Two separate systems
FDA clearance or approval and patent protection answer different questions. The FDA looks at safety and effectiveness, the patent office looks at whether the invention is new and not obvious, and neither decides anything for the other. A device can reach the market without any patent, and a patented device still needs regulatory authorization. Some devices that go through the lengthier premarket approval process may qualify for an extension of patent term to make up for regulatory delay, while devices cleared through a shorter route generally do not. Patents in this field can cover the device's structure, methods of making it, and methods of using it, and each raises its own enforcement questions.
Disclosure during development
Clinical work, conference abstracts, investor decks, and conversations with hospitals can all count as public disclosures if they are not covered by confidentiality. Filing before those events, or making sure they happen under appropriate agreements, preserves options, especially outside the US, where grace periods are limited or absent. Collaborations with physicians and universities raise ownership questions, because their contributions may make them inventors and their institutions may have policies claiming rights. Design history files kept for regulatory purposes can double as invention records, so it helps when they are dated and complete. Gather lab notebooks, design records, collaboration and consulting agreements, and a timeline of disclosures.
Competitors and freedom to operate
Device markets are crowded with patents, so a freedom-to-operate review often matters as much as filing your own applications. Testing done to support FDA submissions may fall within a statutory safe harbor from infringement, although the edges of that safe harbor are contested. Diagnostic methods face added eligibility hurdles in the US. A competitor's patent is often easier to design around early, while changes are cheap, than after tooling and regulatory submissions have fixed the design. For a device company, we review the device, its regulatory path, and the disclosure record, and set priorities for filings and clearance work.
